Latest news with #Septerna
Business Insider
18-05-2025
- Business
- Business Insider
Cantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN)
Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Septerna, Inc. (SEPN – Research Report) on May 15 and set a price target of $25.00. The company's shares closed yesterday at $9.84. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Schimmer is a 5-star analyst with an average return of 11.0% and a 48.74% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, BridgeBio Pharma, and Aardvark Therapeutics, Inc.. In addition to Cantor Fitzgerald, Septerna, Inc. also received a Buy from TD Cowen's Yaron Werber in a report issued on May 15. However, yesterday, Wells Fargo maintained a Hold rating on Septerna, Inc. (NASDAQ: SEPN). Based on Septerna, Inc.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $219 thousand and a GAAP net loss of $21.48 million. In comparison, last year the company earned a revenue of $118 thousand and had a net profit of $34.89 million Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SEPN in relation to earlier this year. Most recently, in March 2025, Ezekowitz Alan, a Director at SEPN bought 13,319.00 shares for a total of $92,167.48.
UPI
16-05-2025
- Business
- UPI
Novo Nordisk, U.S. biotech company team up to create obesity pills
Novo Nordisk will pay all the research and development costs for the project to develop new obesity pills. Photo by Towfiqu barbhuiya/ Pexels May 16 (UPI) -- Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up to $2.2 billion for Septerna. This includes more than $200 million in upfront and short-term milestone payments, plus future rewards tied to research, development and sales. Septerna will also get royalties on any future product sales, The Wall Street Journal reported. Novo Nordisk will pay all the research and development costs for the project. The U.S. biotech company has developed a platform that finds and develops drugs that target special proteins called G protein-coupled receptors. These proteins help pass chemicals from outside cells to the inside. Many major drugs on the market today also target GPCRs. Novo Nordisk's best-known drug, Wegovy, targets a GPCR called GLP-1. Eli Lilly's popular weight-loss drug Zepbound targets both GLP-1 and another GPCR called GIP. "Septerna has demonstrated strong capabilities in GPCR drug discovery," Marcus Schindler, chief scientific officer at Novo Nordisk, told The Wall Street Journal. "We are excited about the opportunity to develop oral small molecule medicines directed at multiple targets," he added. The two companies plan four programs to create pills that target GPCRs including GLP-1, GIP and glucagon -- which are important proteins involved in blood sugar and appetite control, The Journal said. Right now, leading weight-loss drugs must be injected into the body. Pill versions could make the drugs more convenient for patients and easier to ship and store. About one-third of drugs approved by the U.S. Food and Drug Administration target GPCRs, according to Novo Nordisk. But an estimated 75% of GPCR targets have not yet been used in medicine, meaning there's still a big opportunity for discovery. Septerna's stock jumped 69% in premarket trading after the deal was announced. Novo Nordisk's stock rose 1.2% in European trading. More information The Mayo Clinic has more on prescription weight-loss drugs. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
15-05-2025
- Business
- Yahoo
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license agreement with Danish pharma company, Novo Nordisk NVO, for developing and commercializing oral small molecule medicines for treating obesity, type 2 diabetes and other cardiometabolic diseases. Year to date, shares of Septerna have plunged 55.7% compared with the industry's decline of 8.4%. Image Source: Zacks Investment Research Both companies will jointly conduct research and development activities, as well as candidate selection. NVO will bear all research and development costs for the partnered programs, starting with the investigational new drug enabling activities. Septerna will have the right to opt into a global profit-sharing for one of the product candidates in place of future milestone and royalty payments. Under the deal, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including an upfront payment of $200 million and near-term milestone payments. SEPN is also entitled to receive tiered royalties on global net sales if a product is commercialized as a result of the above collaboration. The transaction is expected to be closed later in the second quarter of 2025, subject to customary closing conditions. Per the agreement, both SEPN and NVO plan to start four development programs for potential small molecule therapies for key G protein-coupled receptor (GPCR) targets, including GLP-1, GIP and glucagon receptors. GPCRs represent a large family of cell surface receptors that transmit signals across cell membranes. The partnership aims to leverage Septerna's expertise in GPCR drug discovery with Novo Nordisk's leadership and innovation in the field of obesity and cardiometabolic diseases. With the latest agreement with Septerna, Novo Nordisk aims to expand its presence in the highly competitive obesity treatment market. The company is rapidly developing a pipeline of oral therapies to diversify from its injectable GLP-1 products, including Wegovy and Ozempic (semaglutide). The deal with SEPN for developing oral obesity pills should complement NVO's obesity pipeline, as oral drugs are easier to use compared to injections, which can improve patient adherence. Year to date, shares of Novo Nordisk have lost 25.1% compared with the industry's decline of 5.8%. Image Source: Zacks Investment Research Competition in the obesity market is intensifying. The market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Eli Lilly LLY and Novo Nordisk presently dominate the market. Lilly's popular tirzepatide medicines include diabetes drug Mounjaro and weight loss medicine, Zepbound. However, to stifle increasing competition from Eli Lilly, Novo Nordisk is developing new obesity treatments to stay ahead, especially in the U.S. market. A regulatory application seeking the approval of oral semaglutide 25 mg for weight management is currently under review by the FDA. A final decision from the regulatory body is expected around the turn of the year. Meanwhile, CVS Caremark, a major pharmacy benefit manager ('PBM'), recently announced that it would make NVO's Wegovy its preferred GLP-1 therapy for weight loss, effective July 1. This is likely to give NVO a commercial advantage over its arch rival Lilly in the obesity market. Several other companies like Amgen AMGN and Viking Therapeutics are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and type II diabetes, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. If successfully developed, AMGN and VKTX's products can pose strong competition to LLY's Mounjaro/Zepbound and NVO's Ozempic/Wegovy in the future. Others like Roche, Merck and AbbVie are also looking to enter the obesity space by in-licensing obesity candidates from smaller biotechs. Septerna and Novo Nordisk currently carry a Zacks Rank #3 (Hold) each. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Septerna, Inc. (SEPN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15-05-2025
- Business
- Business Insider
J.P. Morgan Remains a Buy on Septerna, Inc. (SEPN)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Septerna, Inc. (SEPN – Research Report) yesterday. The company's shares closed yesterday at $10.16. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Joseph covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Bluebird Bio, and Rocket Pharmaceuticals. According to TipRanks, Joseph has an average return of 3.0% and a 46.12% success rate on recommended stocks. Currently, the analyst consensus on Septerna, Inc. is a Moderate Buy with an average price target of $19.00. Based on Septerna, Inc.'s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $212 thousand and a GAAP net loss of $20.67 million. In comparison, last year the company earned a revenue of $118 thousand and had a net profit of $34.89 million Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SEPN in relation to earlier this year. Most recently, in March 2025, Ezekowitz Alan, a Director at SEPN bought 13,319.00 shares for a total of $92,167.48.
Yahoo
14-05-2025
- Business
- Yahoo
Eli Lilly Shares Tumble After Rival Novo?Nordisk Strikes Major Weight Loss Deal
Eli Lilly (NYSE:LLY) shares slid more than 3% on Wednesday after reports emerged that Novo Nordisk (NYSE:NVO) has struck a licensing deal with Septerna (NASDAQ:SEPN) to co-develop obesity, Type 2 diabetes, and metabolic therapies. Under the agreement, Novo Nordisk could pay Septerna up to $2.2 billion in milestones, bolstering its pipeline beyond the high-selling Wegovy injectable. Wegovy generated more than $8 billion in 2024 but faces growing competition as investors eye a $150 billion obesity market. Novo Nordisk already secured U.S. regulators' acceptance of an oral Wegovy submission, potentially the first pill for obesity. Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient weight?loss pills. Investors will watch upcoming trial readouts and regulatory decisions closely. As Novo Nordisk and Eli Lilly vie for obesity leadership, each licensing move and clinical milestone is likely to sway market sentiment. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
